Enzyme replacement therapy for mucopolysaccharidosis VI: A phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study
Paul Harmatz(Unknown), Stuart J. Swiedler(Hospital de São João), Janet Wittes(Deloitte (United States)), Zi‐Fan Yu(Johannes Gutenberg University Mainz), Ida Vanessa Döederlein Schwartz(Services Hospital), Maurizio Scarpa(Unknown), Ann M. Lowe(Hôpital Edouard Herriot), Nathalie Guffon(Hôpital Edouard Herriot), Elisa Leão Teles(Hospital de São João), Kenneth I. Berger(New York University), Laila Arash(University of Padua), Roberto Giugliani(Universidade Federal do Rio Grande do Sul), Clara Sá-Miranda(Universidade do Porto), Michael Beck(Eastern Illinois University), Mary S. Newman(University of Padua), J. E. Wraith(Boston Children's Hospital), Emil Kakkis(BioMarin (United States))
Cited by 364
Related Papers
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
|Survey of Anesthesiology|2000|2.9k
Celecoxib for the Prevention of Sporadic Colorectal Adenomas
|New England Journal of Medicine|2006|1k
Bardoxolone Methyl in Type 2 Diabetes and Stage 4 Chronic Kidney Disease
|New England Journal of Medicine|2013|990
Physiologic Evaluation of the Patient With Lung Cancer Being Considered for Resectional Surgery
|CHEST Journal|2013|901
Patiromer in Patients with Kidney Disease and Hyperkalemia Receiving RAAS Inhibitors
|New England Journal of Medicine|2014|658